ClinicalTrials.gg
CompletedNCT06255834Updated Apr 17, 2026Results posted

Phase 1 Study for IPG11406 in Health Volunteer

A Phase 1 interventional study of IPG11406 in Inflammatory Bowel Diseases, sponsored by Nanjing Immunophage Biotech Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by Nanjing Immunophage Biotech Co., Ltd · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 112 studies in Inflammatory Bowel Diseases with a site in China — 49 open to participants now, 53 under way, 5 of them phase 3. Inflammatory Bowel Diseases · China.

Enrollment
42nd of 58
66 · median 97
Started
2024
with 11 others
Phase 1
13 of 112
6 open now
Registered
59th of 112
by date

Among the 112 studies in Inflammatory Bowel Diseases with a site in China, this one is the 42nd largest by enrollment of the 58 interventional ones that give a count, is one of 12 that started in 2024, is one of 13 in phase 1, and was the 59th registered.

Inflammatory Bowel Diseases

1,550 studies on the registry are indexed under Inflammatory Bowel Diseases; 423 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

49 of the 112 studies in Inflammatory Bowel Diseases with a site in China are open now. Recruiting first, the newest first:

44 more — sign in →

All 49 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 133 (48%) set no upper age limit and 116 (42%) stop at 75 or younger; 76 take children under 18; 61 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 112 studies in Inflammatory Bowel Diseases with a site in China, or all of them as a file.
02

Study summary

A phase 1, randomized, double-blind, placebo-controlled, single and multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetics (PK) and food effect of orally administered IPG11406 in healthy adult participants

Read the detailed description

This is a phase 1, randomized, double-blind, placebo-controlled, single and multiple dose escalation study to evaluate the safety, tolerability, PK and food effect of orally administered IPG11406 in healthy adult participants. The study will involve two sequential parts: a single ascending dose (SAD) period (Part A) followed by a multiple ascending dose (MAD) period (Part B).

Part A Dose escalation will start from 0.5 mg. Currently, the 6 dose cohorts are Cohort 1 (0.5 mg), Cohort 2 (2 mg), Cohort 3 (6 mg), Cohort 4 (20 mg), Cohort 5 (40 mg), Cohort 6 (80 mg). About 42 healthy adult participants are being sequentially enrolled in 6 cohorts.

There are 6 participants in Cohort 1 to Cohort 3. In each cohort, 4 participants will receive IPG11406 and 2 participants will receive the placebo as per the randomization code.

Approximately 8 participants will be enrolled in Cohort 4 to Cohort 6 respectively; in each cohort, 6 participants will receive IPG11406 and 2 participants will receive the placebo as per the randomization code.

In each Cohort, 2 sentinel participants will be dosed at least 48 hours prior to the remaining participants. One sentinel will be dosed with IPG11406 and the other with a matching placebo. The remaining participants will be dosed only if no significant safety issues are identified in the sentinel participants. Doses and sampling intervals may be modified based on the PK and safety data that emerges throughout the study.

One of the SAD (Cohort 5 is tentatively to be selected, it may be modified based on the decision of SMC meeting.) cohorts will be selected to assess the effect of food on the pharmacokinetic parameters and referred to as the food effect (FE) cohort. Participants in this cohort will be requested to return to the clinical site to receive a second dose of IPG11406 or placebo after the administration of a meal, upon completion of the 4-day safety follow up period after their first dose. The second dose of IPG11406 or placebo will be administered following a standardized high fat meal (total calories approximately 800 to 1000 calories, with approximately 50% of total calories from fat).

Healthy participants will be screened within 28 days prior to dosing. Participants in the SAD cohorts (including FE cohort) will be admitted to the study site on Day -1 for a total of 6 days. Administration of a single dose of IPG11406 or the placebo will occur on Day 1 under fasted conditions (Following an overnight fast of at least 10 hours, subjects will receive a single dose of IPG11406 or placebo with 240 mL water. Water can be ingested as desired except for 1 hour pre-dose until one hour post dose.). Participants will be discharged on Day 5 following collection of samples for PK analyses and the completion of safety assessments. A follow-up visit will occur on Day 8.

Participants in the FE cohort will be admitted to the study site for at least 10 days for the 2 administrations of IPG11406. A washout of ≥ 4 days will be included between investigational product (IP) administrations. Administration of a single dose of IPG11406 or placebo will occur on Day 1 under fasted condition, and Day 6 (anticipated) under postprandial condition. Following completion of all safety assessments and sampling for PK analyses, subjects will be discharged on Day 10 (anticipated) after the second dose. There will be a follow-up visit on Day 13 (anticipated) after the single dose administration in each period.

Once the final participant in the cohort has completed the Day 5 assessments and been discharged, the Safety Monitoring Committee (SMC) will review cumulative blinded safety data (including follow-up visit data from preceding cohorts) and available PK data to determine the safety and tolerability of the study drug. If the dose level is determined to be safe and well-tolerated, the next dose cohort will be enrolled and randomized in preparation to receive the next dose level of IPG11406 or the placebo.

Part B Three dose levels (10 mg, 20 mg and 40 mg) are anticipated to be evaluated in the MAD, once daily. There will be approximately 8 subjects per cohort, 6 subjects will receive IPG11406 and 2 subjects will receive placebo per the randomization code.

For Cohort M1 (10 mg), the MAD phase will commence following the establishment of the safety and tolerability of Cohort 4 (20 mg) in the SAD. The SMC will evaluate the safety, tolerability and PK data obtained from the participants of cohort 4 in the SAD to determine if the Cohort M1 will be enrolled and randomized to receive the 10 mg multiple dose levels of IPG11406 or placebo.

For Cohort M2 (20 mg), the SMC will evaluate the safety, tolerability and PK data obtained from the participants of cohort 5 (40 mg) in the SAD as well as the safety and PK data from Cohort M1 to determine if the Cohort M2 will be enrolled and randomized to receive the 20 mg multiple dose levels of IPG11406 or placebo.

For Cohort M3 (40 mg), the SMC will evaluate the safety, tolerability and PK data obtained from the participants of cohort 6 (80 mg) in the SAD as well as the safety and PK data from Cohort M2 to determine if the Cohort M3 will be enrolled and randomized to receive the 40 mg multiple dose levels of IPG11406 or placebo.

All subjects will be screened within 28 days prior to dosing and will be admitted to the study site on Day -1. Dosing will start on the morning of Day 1 and will continue over a 10-day period at each dose level. Blood draws will be collected for the assessment of PK parameters. Participants will be discharged on Day 14 following completion of all PK sample collection and safety assessments. There will be a follow-up visit 7 days after the last dose.

Once the final participant in the cohort has completed the Day 14 assessments and been discharged, the SMC will review blinded cumulative safety data (including the follow-up visit data) and available PK data to determine the safety and tolerability of the study drug.

03

Conditions studied

  • Inflammatory Bowel Diseases
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following criteria to be included in the study:

Demography

  1. Healthy volunteers aged between 18 and 50 years old, both male and female, are required. Participants must undergo medical history investigation, physical examination, vital signs examination, , chest X-ray examina-tion, and laboratory tests during the screening period to ensure good health.
  2. The (BMI) is between 18 and 32, calculated as: BMI= weight(kg)/ height 2(m 2);
  3. Participants were required to be in a non-menstrual, non-pregnant, and non-lactating period during the trial and to agree to have no childcare plans for the next 6 months.
  4. Physical health, defined as: detailed and clear medical history, comprehensive physical examination (including blood pressure and pulse rate, laboratory tests, and 12-lead electrocardiogram) with no clinical abnormalities detected;
  5. After 10 minutes of supine position testing, vital signs should be within the following range: 95 mmHg \<systolic blood pressure (SBP) \<140 mmHg 45 mmHg \<Diastolic Blood Pressure (DBP) \<90 mmHg 45 bpm \<Heart Rate (HR) \<90 bpm
  6. After 10 minutes of resting supine position, 12-lead ECG readings: PR interval\<120 ms \<220 ms, QRS complex \<120 ms, (Fridericia recommendedalgorithm) ≤450 ms, normal ECG; or abnormal ECG results deemed clinically insignificant by the investigator.
  7. Laboratory test results must fall within the normal range (or within the established screening threshold) or show no abnormalities; however, serum creatinine, alkaline phosphatase, and liver enzymes (,Alanine aminotransferase (ALT) should not exceed the upper limit of the laboratory normal range. Total should not exceed 1.5 times the for conjugated bilirubin (unless the subject has a history of Gilbert syndrome).
  8. Willing and able to comply with all treatment, and laboratory testing protocols, agree to take the oral test medication, and meet other study requirements
  9. requirements for female subjects:

    1. Fertile female participants: Must undergo a urine pregnancy test during the screening period with a negative result, and agree to use effective contraception for 3 months after signing the until the last dose of the drug. Contraception must always be strictly followed according to the instructions of the contraceptive product and the investigator. Effective contraception includes: complete abstinence, intra- uterine device (IUD) or intrauterine contraceptive system (IUS), double- barrier method (e.g., spermicide plus male condom, female condom, diaphragm, cervical cap, or intrauterine device), or a partner who has undergone vasectomy and whose semen cannot be detected for sperm. b. Fertile women: This includes women (with complete cessation of menstruation for ≥1 year) or women with surgical records of hysterectomy, bilateral oophorectomy, or bilateral salpingectomy (as opposed to tubal ligation). Fertile women do not need to adhere to the listed contraceptive measures. 10. Contraceptive requirements for male subjects: Male subjects must agree to use the listed effective contraceptive methods or have undergone vasectomy within 3 months after signing the informed consent and receiving the last dose ofthe investigational drug. 11. Participants must provide informed consent for this study prior to enrollment and voluntarily sign a written informed consent form.

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following criteria will be excluded from the study:

Medical history and clinical status

1. History of severe cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immune, dermatological, neurological, or psychiat ric disorders. 2. Abnormal chest X-ray findings. 3. Recurrent headache and/or migraine, recurrent nausea and/or vomiting (vomiting only: more than twice a month). 4. Blood donation within 2 months prior to inclusion is permitted, with no volume restrictions. 5. Symptomatic or asymptomatic orthostatic hypotension: defined as a drop in systolic blood pressure of ≥30 mmHg within 3 minutes when changing from supine to standing position. 6. History of drug allergy or confirmed allergic disease. 7. Known to be allergic to any component ofthe pharmaceutical preparation. 8. History of drug or alcohol abuse (regular daily alcohol intake exceeding 40 mL). 9. Heavy smokers (smoking 5 or more cigarettes per day). For light smokers (smoking fewer than 5 cigarettes per day), smoking should be discontinued during the trial period. 10. Individuals who consume excessive amounts oftea or coffee (more than 8 cups per day). 11. Take any medication within 14 days before inclusion or within 5 times the half-life or pharmacodynamic half-life ofthe medication; 12. Eat any citrus fruit (e.g. grapefruit, orange) or juice in the 5 days before selection. 13. Any vaccination within 28 days prior to inclusion and any injection of a biological agent (antibody or its derivative) within 4 months. 14. According to the investigators' assessment, the subjects may have poor compliance during the study or may not be able to cooperate due to language issues or intellectual developmental delays. 15. Participants were registered or had previously participated in any other clinical study involving a drug clinical trial or any other type of medical research within 3 months prior to enrollment or within the 5 half-life period (whichever is shorter). 16. Participants who could not be contacted in an emergency. 17. Researchers or associate researchers, research assistants, pharmacists, study coordinators, or other staff members who are directly or indirectly involved in the study, or anyone associated with the study site (including employees or immediate family members). 18. Any of the following tests are positive: surface antigen (HBsAg), hepatitis B core antigen (anti-HBcAg), anti- antibody, anti- 1 and 2 antibody (anti-HIV1 and anti-HIV2 Ab), or Treponema pallidum antibody. 19. Positive urine drug screening (amphetamines/methamphetamine, barbiturates, benzodiazepines, cannabinoids, cocaine, opioids). 20. Alcohol test positive. 21. Subjects with difficulty in venous blood collection.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    Cohort 1 (SAD - 0.5 mg)

    4 subjects in this cohort will receive a single dose of IPG11406 0.5 mg qd and 2 subjects will receive a single dose of placebo 0.5 mg qd orally.

    Drug: IPG11406

  • Experimental
    Cohort 2 (SAD - 2 mg)

    4 subjects in this cohort will receive a single dose of IPG11406 2 mg qd and 2 subjects will receive a single dose of placebo 2 mg qd orally.

    Drug: IPG11406

  • Experimental
    Cohort 3 (SAD - 6 mg)

    4 subjects in this cohort will receive a single dose of IPG11406 6 mg qd and 2 subjects will receive a single dose of placebo 6 mg qd orally.

    Drug: IPG11406

  • Experimental
    Cohort 4 (SAD - 20 mg)

    6 subjects in this cohort will receive a single dose of IPG11406 20 mg qd and 2 subjects will receive a single dose of placebo 20 mg qd orally.

    Drug: IPG11406

  • Experimental
    Cohort 5 (SAD - 40 mg)

    6 subjects in this cohort will receive a single dose of IPG11406 40 mg qd and 2 subjects will receive a single dose of placebo 40 mg qd orally.

    Drug: IPG11406

  • Experimental
    Cohort 6 (SAD - 80 mg)

    6 subjects in this cohort will receive a single dose of IPG11406 80 mg qd and 2 subjects will receive a single dose of placebo 80 mg qd orally.

    Drug: IPG11406

  • Experimental
    Cohort 7 (MAD - 10 mg)

    6 subjects in this cohort will receive a dose of IPG11406 10 mg qd and 2 subjects will receive a dose of placebo 10 mg qd orally from Day 1 to 10-day.

    Drug: IPG11406

  • Experimental
    Cohort 8 (MAD - 20 mg)

    6 subjects in this cohort will receive a dose of IPG11406 20 mg BID and 2 subjects will receive a dose of placebo 20 mg BID orally from Day 1 to 10-day.

    Drug: IPG11406

  • Experimental
    Cohort 9 (MAD - 40 mg)

    6 subjects in this cohort will receive a dose of IPG11406 40 mg qd and 2 subjects will receive a dose of placebo 40 mg qd orally from Day 1 to 10-day.

    Drug: IPG11406

Interventions

  • IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 0.5 mg, 10 mg and 40 mg Storage:15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 or placebo tablets are orally administered once on Day 1 (Part A) or daily for 10 days from Day 1 to Day 10 (Part B) in a fasted state. Oral doses will be administered with 240 ml of water. Tablets should not be chewed or crushed. Participants in the FE Cohort will receive a second single dose of IPG11406 following a standardized high fat meal upon ≥4 days washout period after the first dose. IPG11406 Placebo Placebo tablets: tablets identical to IPG11406 tablets

    Also known as: IPG11406 Placebo

06

What researchers measure

Primary outcomes

  1. Safety Indicators:Adverse Event

    Time frame: from first dose until end of follow-up, up to 17 days

Secondary outcomes

  1. Pharmacokinetic Indicators: Maximum Plasma Concentration (Cmax)

    Peak concentration. It is directly obtained from the actual measured data of blood drug concentration-time. Steady-state maximum plasma concentration. Obtained directly from the measured plasma concentration-time data. Cohort1-Cohort6:Day 1, 6 hours before administration (within 1 hour); after administration, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96 hours Cohort7-Cohort9:Day 1: Before administration (within 1 hour), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24 hours after administration. Day 4, Day 6, Day 8: Before administration (within 1 hour before administration). Day 10: Before administration (within 1 hour before administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96 hours after administration.

    Time frame: Up to 10 days

  2. Pharmacokinetic Indicators: Area Under the Plasma Concentration Versus Time Curve (AUC)

    From the last administration to the area under the blood concentration-time curve of the last measurable concentration. Calculated using the linear trapezoidal method: AUC(i, i+1) = (Ti+1 - Ti)(Ci + Ci+1) / 2, AUC0-t is the sum of all AUC(i, i+1). Cohort1-Cohort6:Day 1, 6 hours before administration (within 1 hour); after administration, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96 hours Cohort7-Cohort9:Day 1: Before administration (within 1 hour), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24 hours after administration. Day 4, Day 6, Day 8: Before administration (within 1 hour before administration). Day 10: Before administration (within 1 hour before administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96 hours after administration.

    Time frame: Up to 10 days

  3. Pharmacokinetic Indicators:Time to Maximum Concentration (Tmax)

    Steady-state time to Cmax. Obtained directly from the measured plasma concentration-time data. Defined as the time of the first occurrence of Cmin, ss (when there are multiple maximum plasma concentrations), unless otherwise specified

    Time frame: Up to 10 days

07

Results

Posted Apr 17, 2026

Participant flow

Participant flow — Overall Study
MilestoneCohort 1 (SAD - 0.5 mg)Cohort 2 (SAD - 2 mg)Cohort 3 (SAD - 6 mg)Cohort 4 (SAD - 20 mg)Cohort 5 (SAD - 40 mg)Cohort 6 (SAD - 80 mg)Cohort 7 (MAD - 10 mg)Cohort 8 (MAD - 20 mg)Cohort 9 (MAD - 40 mg)Placebo(SAD)Placebo(MAD)
Started444666666126
Completed444666666126
Not completed00000000000

Outcome measures

PrimarySafety Indicators:Adverse Event
Time frame:
from first dose until end of follow-up, up to 17 days
Reported as:
Count of participants · Participants
Safety Indicators:Adverse Event
ParticipantsCohort 1 (SAD - 0.5 mg)Cohort 2 (SAD - 2 mg)Cohort 3 (SAD - 6 mg)Cohort 4 (SAD - 20 mg)Cohort 5 (SAD - 40 mg)Cohort 6 (SAD - 80 mg)Cohort 7 (MAD - 10 mg)Cohort 8 (MAD - 20 mg)Cohort 9 (MAD - 40 mg)Placebo(SAD)Placebo(MAD)
adverse events13234546565
SecondaryPharmacokinetic Indicators: Maximum Plasma Concentration (Cmax)

Peak concentration. It is directly obtained from the actual measured data of blood drug concentration-time. Steady-state maximum plasma concentration. Obtained directly from the measured plasma concentration-time data. Cohort1-Cohort6:Day 1, 6 hours before administration (within 1 hour); after administration, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96 hours Cohort7-Cohort9:Day 1: Before administration (within 1 hour), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24 hours after administration. Day 4, Day 6, Day 8: Before administration (within 1 hour before administration). Day 10: Before administration (within 1 hour before administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96 hours after administration.

Time frame:
Up to 10 days
Reported as:
Mean · ng/mL
Pharmacokinetic Indicators: Maximum Plasma Concentration (Cmax)
ng/mLCohort 1 (SAD - 0.5 mg)Cohort 2 (SAD - 2 mg)Cohort 3 (SAD - 6 mg)Cohort 4 (SAD - 20 mg)Cohort 5 (SAD - 40 mg)Cohort 6 (SAD - 80 mg)Cohort 7 (MAD - 10 mg)Cohort 8 (MAD - 20 mg)Cohort 9 (MAD - 40 mg)
The Cmax data of the SAD group and the single-dose administration (D1) of the MAD group6.18 ± 1.81227.31 ± 7.69567.32 ± 23.190271.48 ± 107.191559.09 ± 131.9921100.48 ± 506.708141.76 ± 48.814245.97 ± 44.820552.85 ± 194.225
The Cmax data of the MAD group after multiple administrations (D10)——————164.79 ± 66.293284.4 ± 61.490573.69 ± 168.739
SecondaryPharmacokinetic Indicators: Area Under the Plasma Concentration Versus Time Curve (AUC)

From the last administration to the area under the blood concentration-time curve of the last measurable concentration. Calculated using the linear trapezoidal method: AUC(i, i+1) = (Ti+1 - Ti)(Ci + Ci+1) / 2, AUC0-t is the sum of all AUC(i, i+1). Cohort1-Cohort6:Day 1, 6 hours before administration (within 1 hour); after administration, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96 hours Cohort7-Cohort9:Day 1: Before administration (within 1 hour), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24 hours after administration. Day 4, Day 6, Day 8: Before administration (within 1 hour before administration). Day 10: Before administration (within 1 hour before administration), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 9, 12, 24, 36, 48, 72, 96 hours after administration.

Time frame:
Up to 10 days
Reported as:
Mean · h*ng/mL
Pharmacokinetic Indicators: Area Under the Plasma Concentration Versus Time Curve (AUC)
h*ng/mLCohort 1 (SAD - 0.5 mg)Cohort 2 (SAD - 2 mg)Cohort 3 (SAD - 6 mg)Cohort 4 (SAD - 20 mg)Cohort 5 (SAD - 40 mg)Cohort 6 (SAD - 80 mg)Cohort 7 (MAD - 10 mg)Cohort 8 (MAD - 20 mg)Cohort 9 (MAD - 40 mg)
The AUC data of the SAD group and the single-dose administration (D1) of the MAD group25.16 ± 15.438162.03 ± 70.235569.74 ± 504.4351353.59 ± 876.6246609.03 ± 2892.93811104.87 ± 7518.955683.93 ± 357.850752.81 ± 132.7392736.13 ± 1397.644
The AUC data of the MAD group after multiple administrations (D10)——————1627.45 ± 1274.247993.57 ± 253.3815321.30 ± 5011.186
SecondaryPharmacokinetic Indicators:Time to Maximum Concentration (Tmax)

Steady-state time to Cmax. Obtained directly from the measured plasma concentration-time data. Defined as the time of the first occurrence of Cmin, ss (when there are multiple maximum plasma concentrations), unless otherwise specified

Time frame:
Up to 10 days
Reported as:
Mean · h
Pharmacokinetic Indicators:Time to Maximum Concentration (Tmax)
hCohort 1 (SAD - 0.5 mg)Cohort 2 (SAD - 2 mg)Cohort 3 (SAD - 6 mg)Cohort 4 (SAD - 20 mg)Cohort 5 (SAD - 40 mg)Cohort 6 (SAD - 80 mg)Cohort 7 (MAD - 10 mg)Cohort 8 (MAD - 20 mg)Cohort 9 (MAD - 40 mg)
TheTmax data of the SAD group and the single-dose administration (D1) of the MAD group2.63 ± 1.8871.63 ± 0.2503.13 ± 1.0312.5 ± 1.4832.25 ± 1.1732.42 ± 1.4632.67 ± 1.1692.08 ± 1.5302.17 ± 1.080
The Tmax data of the MAD group after multiple administrations (D10)——————2.75 ± 1.0372.17 ± 1.4381.92 ± 1.242

Adverse events

Collected over from first dose until end of follow-up, up to 17 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1 (SAD - 0.5 mg)0/4 (0%)0/4 (0%)1/4 (25%)
Cohort 2 (SAD - 2 mg)0/4 (0%)0/4 (0%)3/4 (75%)
Cohort 3 (SAD - 6 mg)0/4 (0%)0/4 (0%)2/4 (50%)
Cohort 4 (SAD - 20 mg)0/6 (0%)0/6 (0%)3/6 (50%)
Cohort 5 (SAD - 40 mg)0/6 (0%)0/6 (0%)4/6 (66.7%)
Cohort 6 (SAD - 80 mg)0/6 (0%)0/6 (0%)5/6 (83.3%)
Cohort 7 (MAD - 10 mg)0/6 (0%)0/6 (0%)4/6 (66.7%)
Cohort 8 (MAD - 20 mg)0/6 (0%)0/6 (0%)6/6 (100%)
Cohort 9 (MAD - 40 mg)0/6 (0%)0/6 (0%)5/6 (83.3%)
Placebo(SAD)0/12 (0%)0/12 (0%)6/12 (50%)
Placebo(MAD)0/6 (0%)0/6 (0%)5/6 (83.3%)
Most frequent other events
Most frequent other events
EventCohort 1 (SAD - 0.5 mg)Cohort 2 (SAD - 2 mg)Cohort 3 (SAD - 6 mg)Cohort 4 (SAD - 20 mg)Cohort 5 (SAD - 40 mg)Cohort 6 (SAD - 80 mg)Cohort 7 (MAD - 10 mg)Cohort 8 (MAD - 20 mg)Cohort 9 (MAD - 40 mg)Placebo(SAD)Placebo(MAD)
InvestigationsInvestigations1/42/42/43/64/64/63/66/65/64/125/6
Sinus bradycardiaCardiac disorders0/41/40/40/60/61/60/60/60/61/120/6
Infection upper respiratoryInfections and infestations0/40/41/40/60/60/60/60/60/60/120/6
Wandering pacemakerCardiac disorders0/40/40/40/60/60/60/60/60/62/120/6
Oropharyngeal painReproductive system and breast disorders0/40/40/40/60/60/60/60/61/60/120/6
Abdominal painGastrointestinal disorders0/40/40/40/60/60/61/60/60/60/120/6
DizzinessNervous system disorders0/40/40/40/60/60/60/60/60/61/120/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1 (SAD - 0.5 mg)Cohort 2 (SAD - 2 mg)Cohort 3 (SAD - 6 mg)Cohort 4 (SAD - 20 mg)Cohort 5 (SAD - 40 mg)Cohort 6 (SAD - 80 mg)Cohort 7 (MAD - 10 mg)Cohort 8 (MAD - 20 mg)Cohort 9 (MAD - 40 mg)Placebo(SAD )Placebo(MAD)Total
<=18 years000000000000
Between 18 and 65 years44466666612666
>=65 years000000000000
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1 (SAD - 0.5 mg)Cohort 2 (SAD - 2 mg)Cohort 3 (SAD - 6 mg)Cohort 4 (SAD - 20 mg)Cohort 5 (SAD - 40 mg)Cohort 6 (SAD - 80 mg)Cohort 7 (MAD - 10 mg)Cohort 8 (MAD - 20 mg)Cohort 9 (MAD - 40 mg)Placebo(SAD )Placebo(MAD)Total
Female0010131023011
Male4436535649655
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1 (SAD - 0.5 mg)Cohort 2 (SAD - 2 mg)Cohort 3 (SAD - 6 mg)Cohort 4 (SAD - 20 mg)Cohort 5 (SAD - 40 mg)Cohort 6 (SAD - 80 mg)Cohort 7 (MAD - 10 mg)Cohort 8 (MAD - 20 mg)Cohort 9 (MAD - 40 mg)Placebo(SAD )Placebo(MAD)Total
American Indian or Alaska Native000000000000
Asian44466666612666
Native Hawaiian or Other Pacific Islander000000000000
Black or African American000000000000
White000000000000
More than one race000000000000
Unknown or Not Reported000000000000
baseline weight
baseline weight(kg)Cohort 1 (SAD - 0.5 mg)Cohort 2 (SAD - 2 mg)Cohort 3 (SAD - 6 mg)Cohort 4 (SAD - 20 mg)Cohort 5 (SAD - 40 mg)Cohort 6 (SAD - 80 mg)Cohort 7 (MAD - 10 mg)Cohort 8 (MAD - 20 mg)Cohort 9 (MAD - 40 mg)Placebo(SAD )Placebo(MAD)Total
Mean69.58 ± 7.02763.10 ± 7.93558.15 ± 4.69267.05 ± 6.96162.78 ± 6.63559.68 ± 9.63964.08 ± 7.36263.48 ± 5.55361.30 ± 7.26663.62 ± 7.79372.08 ± 11.15264.08 ± 8.028
baseline height
baseline height(cm)Cohort 1 (SAD - 0.5 mg)Cohort 2 (SAD - 2 mg)Cohort 3 (SAD - 6 mg)Cohort 4 (SAD - 20 mg)Cohort 5 (SAD - 40 mg)Cohort 6 (SAD - 80 mg)Cohort 7 (MAD - 10 mg)Cohort 8 (MAD - 20 mg)Cohort 9 (MAD - 40 mg)Placebo(SAD )Placebo(MAD)Total
Mean170.50 ± 5.745168.13 ± 8.459161.00 ± 4.143169.75 ± 4.345167.75 ± 5.174164.17 ± 9.042169.58 ± 7.651170.08 ± 7.493164.33 ± 11.165168.68 ± 10.034172.42 ± 10.047168.05 ± 8.212
08

Study locations

1 site
  • Zhejiang Hospital
    Hangzhou, Zhejiang 310013, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2024 to primary completion in Dec 2024, 10 months.

Results were first posted in Apr 2026, 1 year 3 months after primary completion.

Of 35 industry-sponsored phase 1 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 13. This study's 10 months is above that.

Counting every sponsor, half of 51 studies reached it within 12 months; a quarter within 4 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 25, 2023
First posted
Feb 13, 2024
StartActual
Feb 24, 2024
Primary completionActual
Dec 30, 2024
CompletionActual
Dec 30, 2024
Results first posted
Apr 17, 2026
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06255834
Lead sponsor
Nanjing Immunophage Biotech Co., Ltd
Collaborators
Zhejiang Hospital
Responsible party
Sponsor
First posted
Feb 13, 2024
Start date
Feb 24, 2024
Primary completion
Dec 30, 2024
Completion
Dec 30, 2024
Results posted
Apr 17, 2026
Last update
Apr 17, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IPG11406

Start the discussion